IMMray™ SLE

IMMray™ biomarker microarray differentiates systemic lupus erythematosus (SLE) from other autoimmune diseases with 96% accuracy

Immunovia announced in a press release on March 7, 2017, that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s Department of Immuntechnology has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, Sjögren Syndrome and Systemic Vasculitis. There is a clear clinical need for such a test since more than 50% of SLE patients are being initially misdiagnosed, mainly due to ambiguous laboratory test results.

In the first arm of the study, SLE was detected with an accuracy as high as 95% from the RA sample cohort and 99% from the healthy controls. When differentiated from Sjögren Syndrome and Systemic Vasculitis, the accuracy rates of the IMMray™ biomarker signature were 84% and 99%, respectively. In the second arm of the study, SLE could be differentiated from a pool of samples of all the three other autoimmune diseases with an accuracy of 96%.

Immunovia announced in a press release on June 21, 2017 that the IMMray™ biomarker signature could differentiate RA from the other autoimmune diseases with 89% accuracy. In this third data set, the IMMray™ biomarker signature was able to differentiate RA, one of the most common autoimmune diseases, from SLE, Sjögren Syndrome and Systemic Vasculitis, with 89% accuracy. The IMMray™ signatures also detected RA with an accuracy of 98% from the healthy controls. When differentiated from Sjögren Syndrome, and Systemic Vasculitis, the RA accuracy was 83% and 95%, respectively. Finally, Sjögren’s Syndrome and Systemic Vasculitis could also be differentiated with high accuracies from the pools of samples of all the three other autoimmune diseases, at 85% and 94 %, respectively.